Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 14, 2025

The Application Progress of Selinexor in the Treatment of Relapsed and Refractory Multiple Myeloma--Review.

View Full Paper
Ask AI
Bookmark
Share

Authors

YTYuxin TongYTYamin Tan

Discussion

Loading...

Member takes

Overview

Review highlights the clinical effects of selinexor in relapsed and refractory multiple myeloma, suggesting potential benefits.

Key Points

  • Selinexor demonstrates potential to improve clinical response rates in relapsed and refractory multiple myeloma.
  • Treatment with selinexor can enhance patients' quality of life despite some adverse reactions.
  • Preventive measures can help minimize adverse reactions associated with selinexor treatment.
  • Further research is needed to optimize selinexor treatment regimens for broader patient benefits.

Cite This Study

Tong et al. (2025) studied this question.

synapsesocial.com/papers/68c6df6933b72be0b5e43b8fhttps://doi.org/10.19746/j.cnki.issn.1009-2137.2025.04.046
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape2026 · 1 citations
  2. 2Selinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series2024 · 1 citations
  3. 3A novel conditioning regimen combining selinexor with melphalan  Improves Survival in Patients with multiple myeloma:a prospective study2025
  4. 4Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study2024 · 14 citations
  5. 5Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study)2024 · 3 citations